Gainers & Losers
Fri Jan 23 2026 09:55:53- Tech Mahindra share price
- ₹1,702.100.84%
- Hindustan Unilever share price
- ₹2,406.450.69%
- Infosys share price
- ₹1,673.000.58%
- Tata Consultancy Services share price
- ₹3,160.550.30%
- HCL Technologies share price
- ₹1,705.550.17%
Active Stocks
Fri Jan 23 2026 10:29:50- Yes Bank share price
- ₹20.94-3.23%
- Eternal share price
- ₹258.65-6.29%
- Suzlon Energy share price
- ₹45.70-2.85%
- Adani Power share price
- ₹133.05-5.50%
- Canara Bank share price
- ₹151.75-1.91%
Business News/Market/Market Stats/Zydus Lifesciences share price/ Zydus Lifesciences Balance Sheet Annual
Zydus Lifesciences Balance Sheet Annual
885.00 +0.15 (0.02%)Updated : 23 Jan 2026
| Fiscal Period | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
| Total Liabilities Shareholders' Equity | 37,201.70 | 29,280.80 | 25,756.40 | 27,795.40 |
| Accumulated Depreciation Total | -5,619.70 | -5,081.80 | -4,502.60 | -3,905.90 |
| Other Liabilities Total | 1,257.00 | 1,365.70 | 323.20 | 370.20 |
| Accrued Expenses | 1,748.00 | 1,270.20 | 1,307.70 | 1,141.40 |
| Common Stock Total | 100.60 | 100.60 | 101.20 | 102.40 |
| Other Equity Total | -974.20 | -905.20 | -729.50 | -416.10 |
| Other Current Assets Total | 89.60 | 401.30 | 66.50 | 269.80 |
| Prepaid Expenses | 114.40 | 102.10 | 101.60 | 72.10 |
| Total Assets | 37,201.70 | 29,280.80 | 25,756.40 | 27,795.40 |
| Current Portof LT Debt/ Capital Leases | 11.60 | 10.50 | 94.10 | 528.60 |
| Cash | 826.80 | 413.00 | 487.80 | 657.80 |
| Total Equity | 23,953.10 | 19,829.50 | 17,515.80 | 16,999.60 |
| Long Term Investments | 1,557.00 | 969.60 | 1,177.90 | 934.80 |
| Retained Earnings( Accumulated Deficit) | 24,826.70 | 20,634.10 | 18,144.10 | 17,313.30 |
| Total Common Shares Outstanding | 100.62 | 100.62 | 101.22 | 102.37 |
| Property/ Plant/ Equipment Total- Gross | 12,979.60 | 11,996.60 | 11,329.30 | 10,328.50 |
| Tangible Book Valueper Share Common Eq | 153.91 | 118.78 | 114.81 | 102.64 |
| Goodwill Net | 5,242.10 | 5,266.00 | 4,804.40 | 5,364.60 |
| Total Liabilities | 13,248.60 | 9,451.30 | 8,240.60 | 10,795.80 |
| Total Debt | 3,213.20 | 804.20 | 1,194.90 | 4,220.90 |
| Short Term Investments | 6,977.10 | 940.00 | 699.80 | 2,974.90 |
| Cashand Short Term Investments | 7,803.90 | 1,353.00 | 1,187.60 | 4,081.80 |
| Total Receivables Net | 4,943.50 | 6,047.30 | 5,081.60 | 3,939.50 |
| Notes Payable/ Short Term Debt | 3,169.50 | 768.60 | 1,081.00 | 3,314.10 |
| Deferred Income Tax | 512.60 | 446.50 | 194.40 | 153.80 |
| Accounts Receivable- Trade Net | 4,039.80 | 5,231.20 | 4,427.80 | 3,340.30 |
| Property/ Plant/ Equipment Total- Net | 7,359.90 | 6,914.80 | 6,826.70 | 6,422.60 |
| Minority Interest | 2,405.30 | 2,272.10 | 2,172.50 | 2,054.20 |
| Total Current Liabilities | 9,041.60 | 5,341.90 | 5,530.70 | 7,839.40 |
| Total Inventory | 4,094.70 | 3,597.70 | 3,579.10 | 3,898.20 |
| Accounts Payable | 2,305.80 | 2,126.70 | 2,125.00 | 2,137.80 |
| Other Currentliabilities Total | 1,806.70 | 1,165.90 | 922.90 | 717.50 |
| Total Long Term Debt | 32.10 | 25.10 | 19.80 | 378.20 |
| Intangibles Net | 3,223.60 | 2,611.00 | 1,090.50 | 1,127.20 |
| Other Long Term Assets Total | 2,530.40 | 1,842.10 | 1,640.40 | 1,544.90 |
| Note Receivable- Long Term | 242.60 | 175.90 | 200.10 | 139.90 |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 17,046.10 | 11,501.40 | 10,016.40 | 12,261.40 |
| Capital Lease Obligations | 32.10 | 25.10 | 19.80 | 16.10 |
| Long Term Debt | - | 0.00 | 0.00 | 362.10 |
| Cash Equivalents | - | - | - | 449.10 |
*All figures in crores except per share values
Zydus Lifesciences Quick Links
Zydus Lifesciences Dividend Zydus Lifesciences Bonus Zydus Lifesciences News Zydus Lifesciences AGM Zydus Lifesciences Rights Zydus Lifesciences Splits Zydus Lifesciences Board Meetings Zydus Lifesciences Key Metrics Zydus Lifesciences Shareholdings Zydus Lifesciences Profit Loss Zydus Lifesciences Cashflow Zydus Lifesciences Q1 Results Zydus Lifesciences Q2 Results Zydus Lifesciences Q3 Results Zydus Lifesciences Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
418.00+15.50(3.85%)
1,417.45+39.00(2.83%)
189.20+4.85(2.63%)
276.50-6.90 (-2.43%)
4,024.00-56.20 (-1.38%)